NASDAQ:EXAS - EXACT Sciences Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$68.74 -0.59 (-0.85 %)
(As of 06/21/2018 03:31 PM ET)
Previous Close$69.79
Today's Range$67.97 - $69.85
52-Week Range$33.44 - $71.60
Volume79,438 shs
Average Volume2.03 million shs
Market Capitalization$8.47 billion
P/E Ratio-69.01
Dividend YieldN/A
Beta0.86
EXACT Sciences logoExact Sciences Corporation, a molecular diagnostics company, focuses on developing products for the early detection and prevention of various cancers in the United States. The company offers Cologuard, a non-invasive stool-based DNA screening test for the early detection of colorectal cancer and pre-cancer. It has license agreements with MAYO Foundation for Medical Education and Research; and Hologic, Inc. Exact Sciences Corporation was founded in 1995 and is headquartered in Madison, Wisconsin.

Receive EXAS News and Ratings via Email

Sign-up to receive the latest news and ratings for EXAS and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Commercial physical research
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:EXAS
CUSIP30063P10
Phone608-284-5700

Debt

Debt-to-Equity Ratio0.71
Current Ratio15.30
Quick Ratio14.86

Price-To-Earnings

Trailing P/E Ratio-69.01
Forward P/E Ratio-58.25
P/E GrowthN/A

Sales & Book Value

Annual Sales$265.99 million
Price / Sales31.50
Cash FlowN/A
Price / CashN/A
Book Value$4.35 per share
Price / Book15.80

Profitability

EPS (Most Recent Fiscal Year)($0.99)
Net Income$-114,390,000.00
Net Margins-38.61%
Return on Equity-20.92%
Return on Assets-15.73%

Miscellaneous

Employees1,268
Outstanding Shares121,900,000

EXACT Sciences (NASDAQ:EXAS) Frequently Asked Questions

What is EXACT Sciences' stock symbol?

EXACT Sciences trades on the NASDAQ under the ticker symbol "EXAS."

How were EXACT Sciences' earnings last quarter?

EXACT Sciences Co. (NASDAQ:EXAS) released its quarterly earnings results on Thursday, April, 26th. The medical research company reported ($0.33) earnings per share for the quarter, topping the consensus estimate of ($0.38) by $0.05. The medical research company had revenue of $90.30 million for the quarter, compared to analysts' expectations of $86.31 million. EXACT Sciences had a negative net margin of 38.61% and a negative return on equity of 20.92%. The firm's revenue for the quarter was up 86.7% compared to the same quarter last year. During the same period in the previous year, the company earned ($0.32) earnings per share. View EXACT Sciences' Earnings History.

When is EXACT Sciences' next earnings date?

EXACT Sciences is scheduled to release their next quarterly earnings announcement on Tuesday, July, 24th 2018. View Earnings Estimates for EXACT Sciences.

What price target have analysts set for EXAS?

13 Wall Street analysts have issued 12 month target prices for EXACT Sciences' stock. Their predictions range from $41.00 to $85.00. On average, they anticipate EXACT Sciences' stock price to reach $62.8333 in the next year. View Analyst Ratings for EXACT Sciences.

What are Wall Street analysts saying about EXACT Sciences stock?

Here are some recent quotes from research analysts about EXACT Sciences stock:
  • 1. BTIG Research analysts commented, "5 th , data on Exact Sciences’ second case control study for its liver biomarker is scheduled to be presented at the Digestive Disease Week (DDW) conference. Recall that the biomarkers are being co-developed with the Mayo Clinic. The abstract is available on DDW’s website and preliminary details show encouraging 95% sensitivity across all stages (93% specificity in healthy controls, 86% specificity in cirrhotic controls). A liver screening test is one of a number of platforms in EXAS’ cancer pipeline and given the improving traction here, may be the second real shot on the goal, though years away. While we don’t view this as a material stock-moving event, pipeline advancement is supportive of our positive thesis on the name. We reiterate our Buy rating and $70 PT." (6/5/2018)
  • 2. According to Zacks Investment Research, "EXACT Sciences Corporation uses applied genomics to develop effective, patient-friendly screening technologies for use in the detection of cancer. Certain of its technologies have been licensed to Laboratory Corporation of America Holdings for a stool-based DNA screening assay for colorectal cancer in the average-risk population. Colorectal cancer, which is the most deadly cancer among non-smokers, is generally curable if detected early. Despite the availability of colorectal cancer screening and diagnostic tests for more than twenty years, the rate of early detection of colorectal cancer remains low, and deaths from colorectal cancer remain high. EXACT Sciences believes its genomics-based technologies would help to enable detection of colorectal cancer so that more people can be effectively treated. " (6/4/2018)

Are investors shorting EXACT Sciences?

EXACT Sciences saw a drop in short interest in May. As of May 31st, there was short interest totalling 14,066,900 shares, a drop of 8.9% from the May 15th total of 15,439,973 shares. Based on an average daily volume of 1,933,552 shares, the short-interest ratio is presently 7.3 days. Approximately 11.8% of the shares of the stock are short sold. View EXACT Sciences' Current Options Chain.

Who are some of EXACT Sciences' key competitors?

Who are EXACT Sciences' key executives?

EXACT Sciences' management team includes the folowing people:
  • Mr. Kevin T. Conroy, Chairman, Pres & CEO (Age 52)
  • Mr. Jeffrey T. Elliott CFA, CFO & Chief Accounting Officer (Age 40)
  • Mr. Maneesh K. Arora, Sr. VP, COO & Director (Age 49)
  • Dr. Graham P. Lidgard Ph.D., Chief Science Officer and Sr. VP of R&D (Age 69)
  • Mr. D. Scott Coward, Chief Legal Officer, Sr. VP, Gen. Counsel and Sec. (Age 53)

Has EXACT Sciences been receiving favorable news coverage?

Headlines about EXAS stock have trended somewhat positive recently, according to Accern Sentiment Analysis. Accern rates the sentiment of media coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. EXACT Sciences earned a coverage optimism score of 0.05 on Accern's scale. They also gave press coverage about the medical research company an impact score of 46.20 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company's share price in the next several days.

Who are EXACT Sciences' major shareholders?

EXACT Sciences' stock is owned by many different of institutional and retail investors. Top institutional investors include OppenheimerFunds Inc. (4.78%), Zevenbergen Capital Investments LLC (1.67%), Eagle Asset Management Inc. (1.46%), Victory Capital Management Inc. (1.40%), Artisan Partners Limited Partnership (1.23%) and Northern Trust Corp (1.21%). Company insiders that own EXACT Sciences stock include D Scott Coward, David Thompson, Graham Peter Lidgard, Jeffrey Thomas Elliott, Katherine S Zanotti, Kevin T Conroy, Lionel Sterling, Maneesh Arora, Michael S Wyzga and Thomas D Carey. View Institutional Ownership Trends for EXACT Sciences.

Which major investors are selling EXACT Sciences stock?

EXAS stock was sold by a variety of institutional investors in the last quarter, including Antipodean Advisors LLC, Lord Abbett & CO. LLC, Wasatch Advisors Inc., Rock Springs Capital Management LP, Hodges Capital Management Inc., Prudential Financial Inc., Eagle Asset Management Inc. and California Public Employees Retirement System. Company insiders that have sold EXACT Sciences company stock in the last year include D Scott Coward, Graham Peter Lidgard, Jeffrey Thomas Elliott, Katherine S Zanotti, Kevin T Conroy, Maneesh Arora, Michael S Wyzga and Thomas D Carey. View Insider Buying and Selling for EXACT Sciences.

Which major investors are buying EXACT Sciences stock?

EXAS stock was bought by a variety of institutional investors in the last quarter, including OppenheimerFunds Inc., Artisan Partners Limited Partnership, Victory Capital Management Inc., Atlantic Trust Group LLC, Elk Creek Partners LLC, Zweig DiMenna Associates LLC, Frontier Capital Management Co. LLC and Intrinsic Edge Capital Management LLC. Company insiders that have bought EXACT Sciences stock in the last two years include David Thompson, Katherine S Zanotti, Lionel Sterling and Thomas D Carey. View Insider Buying and Selling for EXACT Sciences.

How do I buy shares of EXACT Sciences?

Shares of EXAS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is EXACT Sciences' stock price today?

One share of EXAS stock can currently be purchased for approximately $68.74.

How big of a company is EXACT Sciences?

EXACT Sciences has a market capitalization of $8.47 billion and generates $265.99 million in revenue each year. The medical research company earns $-114,390,000.00 in net income (profit) each year or ($0.99) on an earnings per share basis. EXACT Sciences employs 1,268 workers across the globe.

How can I contact EXACT Sciences?

EXACT Sciences' mailing address is 441 CHARMANY DRIVE, MADISON WI, 53719. The medical research company can be reached via phone at 608-284-5700.


MarketBeat Community Rating for EXACT Sciences (EXAS)

Community Ranking:  3.2 out of 5 (star star star)
Outperform Votes:  609 (Vote Outperform)
Underperform Votes:  339 (Vote Underperform)
Total Votes:  948
MarketBeat's community ratings are surveys of what our community members think about EXACT Sciences and other stocks. Vote "Outperform" if you believe EXAS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe EXAS will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 6/21/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.